hydroxychloroquine has been researched along with Carcinoma, Hepatocellular in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease." | 1.56 | Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. ( Avdic, E; Avery, R; Cameron, AM; Chen, PH; Fine, DM; Garibaldi, B; Garneau, WM; Gurakar, A; Hammami, MB; Jain, T; Kim, AK; Liu, G; Monroy Trujillo, JM; Niranjan-Azadi, A; Petty, B; Shah, P; Strout, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hammami, MB | 1 |
| Garibaldi, B | 1 |
| Shah, P | 1 |
| Liu, G | 1 |
| Jain, T | 1 |
| Chen, PH | 1 |
| Kim, AK | 1 |
| Avdic, E | 1 |
| Petty, B | 1 |
| Strout, S | 1 |
| Fine, DM | 1 |
| Niranjan-Azadi, A | 1 |
| Garneau, WM | 1 |
| Cameron, AM | 1 |
| Monroy Trujillo, JM | 1 |
| Gurakar, A | 1 |
| Avery, R | 1 |
| Bartolini, D | 1 |
| Dallaglio, K | 1 |
| Torquato, P | 1 |
| Piroddi, M | 1 |
| Galli, F | 1 |
| Zhao, Z | 1 |
| Wu, J | 1 |
| Liu, X | 1 |
| Liang, M | 1 |
| Zhou, X | 1 |
| Ouyang, S | 1 |
| Yao, J | 1 |
| Wang, J | 1 |
| Luo, B | 1 |
1 review available for hydroxychloroquine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Chloroquine; Humans; Hydroxychloroquine; Liver Neopla | 2018 |
2 other studies available for hydroxychloroquine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Coronavirus Infections; COVID-19; COVI | 2020 |
Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolife | 2018 |